Laurence Reilly

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 493 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

Mario E. Lacouture, Laurence Reilly, Pedram Gerami et al. · Annals of Oncology · 2008 · 249 citations · Full text

Medicine, Dermatology, Oncology +12

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

Bradley E. Chipps, Frank C. Albers, Laurence Reilly et al. · BMJ Open Respiratory Research · 2021 · 17 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 11 citations

Medicine, Pharmacology, Clinical Pharmacology +11

Applying nurture as a whole school approach

Stephanie. McNicol, Laurence Reilly · Educational and Child Psychology · 2018 · 11 citations

Education, Educational Psychology, Elementary Education +14